Replies to post #135 on Acasti Pharma, Inc (ACST)

[oldberkeley]

I agree, the primary question is one of degree of effect.

However, my thought is that if the data review committee had doubts about efficacy they would have recommended that the trial continue. On the flip side, data may have suggested that as the trial continued the numbers were only going to get worse.

I don't think that the latter is true, so I'm expecting good top-line results.

Either way, I also expect an anticipatory run-up. I have not decided whether to hold through the release.